Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05344482 · ClinicalTrials.gov registry record
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 277
- Enrollment target
NCT05344482: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05344482 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 277 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05344482 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 277 participants
- Enrollment target
Study Summary
This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey. Data were extracted between 02 September 2020 and 29 April 2021.
Primary Outcome
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for
Interventions
- OTHER Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2021-08-31 |
What the finished NCT05344482 record still lists
NCT05344482 is an observational study that tracks outcomes without assigning an intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT05344482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05344482 about?
NCT05344482 is a clinical study titled "Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis". This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey. Data were extracted between 02 September 2020 and 29 April 2021.
What is the current status of trial NCT05344482?
This trial is currently completed. The enrollment target is 277 participants. The study started on 2020-07-09. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT05344482?
The interventions under investigation include: Secukinumab (OTHER).
Who is sponsoring clinical trial NCT05344482?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI